In the world of cell therapy, Silicon Valley has long recognized that technological innovation is the key to solving ...

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...

LOUISVILLE, Ky. -- A CD70-targeted CAR T-cell therapy for advanced kidney cancer continued to show durable activity in ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

have relapsed or refractory ALL after at least two previous lines of therapy, or have disease that relapsed or was refractory ...

Advanced therapy medicinal products (ATMPs) are pushing the boundaries of medicine, offering hope for previously untreatable ...

To improve long-term persistence and reduce the risk of immune rejection, researchers are exploring ways to diminish the ...

The funds will primarily support the company's Phase 1 clinical trial of its lead oncology candidate, VIPER-101, an ...

Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy ...

With more than $80 million in hand, the University of Texas MD Anderson Cancer Center has launched its own cell therapy ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...